CD74: a New Prognostic Factor for Patients with Malignant Pleural Mesothelioma

Overview

Journal Br J Cancer

Specialty Oncology

Date 2014 Mar 6

PMID 24594996

Citations 17

Authors

C Otterstrom

A Soltermann

I Opitz

E Felley-Bosco

W Weder

R A Stahel

F Triponez

J H Robert

V Serre-Beinier

Affiliations

Soon will be listed here.

Abstract

Background: The pro-inflammatory cytokine migration inhibitory factor (MIF) and its receptor CD74 have been proposed as possible therapeutic targets in several cancers. We studied the expression of MIF and CD74 together with calretinin in specimens of malignant pleural mesothelioma (MPM), correlating their expression levels with clinico-pathologic parameters, in particular overall survival (OS).

Methods: Migration inhibitory factor, CD74, and calretinin immunoreactivity were investigated in a tissue microarray of 352 patients diagnosed with MPM. Protein expression intensities were semiquantitatively scored in the tumour cells and in the peritumoral stroma. Markers were matched with OS, age, gender, and histological subtype.

Results: Clinical data from 135 patients were available. Tumour cell expressions of MIF and CD74 were observed in 95% and 98% of MPM specimens, respectively, with a homogenous distribution between the different histotypes. CD74 (P<0.001) but not MIF overexpression (P=0.231) emerged as an independent prognostic factor for prolonged OS. High expression of tumour cell calretinin correlated with the epithelioid histotype and was also predictive of longer OS (P<0.001). When compared with previously characterised putative epithelial-to-mesenchymal transition markers, CD74 correlated positively with tumoral PTEN and podoplanin expressions, but was inversely related with periostin expression.

Conclusions: High expression of CD74 is an independent prognostic factor for prolonged OS in mesothelioma patients.

Citing Articles

Macrophage Migration Inhibitory Factor (MIF) and D-Dopachrome Tautomerase (DDT): Pathways to Tumorigenesis and Therapeutic Opportunities.

Valdez C, Sanchez-Zuno G, Bucala R, Tran T Int J Mol Sci. 2024; 25(9).

PMID: 38732068 PMC: 11084905. DOI: 10.3390/ijms25094849.

CD74 is associated with inflamed tumor immune microenvironment and predicts responsiveness to PD-1/CTLA-4 bispecific antibody in patients with solid tumors.

Wang J, Li X, Xiao G, Desai J, Frentzas S, Wang Z Cancer Immunol Immunother. 2024; 73(2):36.

PMID: 38280003 PMC: 10822011. DOI: 10.1007/s00262-023-03604-2.

Prognostic role of CD74, CD10 and Ki-67 immunohistochemical expression in patients with diffuse malignant peritoneal mesothelioma: a retrospective study.

Liang Y, Li C, Liu Y, Tian L, Yang D BMC Cancer. 2023; 23(1):406.

PMID: 37147569 PMC: 10161649. DOI: 10.1186/s12885-023-10871-w.

Epigenetic Immune Remodeling of Mesothelioma Cells: A New Strategy to Improve the Efficacy of Immunotherapy.

Lofiego M, Cannito S, Fazio C, Piazzini F, Cutaia O, Solmonese L Epigenomes. 2021; 5(4).

PMID: 34968251 PMC: 8715476. DOI: 10.3390/epigenomes5040027.

HLA Class II Histocompatibility Antigen γ Chain (CD74) Expression Is Associated with Immune Cell Infiltration and Favorable Outcome in Breast Cancer.

Noer J, Talman M, Moreira J Cancers (Basel). 2021; 13(24).

PMID: 34944801 PMC: 8699420. DOI: 10.3390/cancers13246179.

References

Schramm A, Opitz I, Thies S, Seifert B, Moch H, Weder W . Prognostic significance of epithelial-mesenchymal transition in malignant pleural mesothelioma. Eur J Cardiothorac Surg. 2009; 37(3):566-72. DOI: 10.1016/j.ejcts.2009.08.027. View

Heinrichs D, Knauel M, Offermanns C, Berres M, Nellen A, Leng L . Macrophage migration inhibitory factor (MIF) exerts antifibrotic effects in experimental liver fibrosis via CD74. Proc Natl Acad Sci U S A. 2011; 108(42):17444-9. PMC: 3198363. DOI: 10.1073/pnas.1107023108. View

Lue H, Thiele M, Franz J, Dahl E, Speckgens S, Leng L . Macrophage migration inhibitory factor (MIF) promotes cell survival by activation of the Akt pathway and role for CSN5/JAB1 in the control of autocrine MIF activity. Oncogene. 2007; 26(35):5046-59. DOI: 10.1038/sj.onc.1210318. View

Datta M, Shahsafaei A, Nadler L, Freeman G, Dorfman D . Expression of MHC class II-associated invariant chain (Ii;CD74) in thymic epithelial neoplasms. Appl Immunohistochem Mol Morphol. 2000; 8(3):210-5. DOI: 10.1097/00129039-200009000-00007. View

Miller E, Li J, Leng L, McDonald C, Atsumi T, Bucala R . Macrophage migration inhibitory factor stimulates AMP-activated protein kinase in the ischaemic heart. Nature. 2008; 451(7178):578-82. DOI: 10.1038/nature06504. View

Hinterberger M, Reineke T, Storz M, Weder W, Vogt P, Moch H . D2-40 and calretinin - a tissue microarray analysis of 341 malignant mesotheliomas with emphasis on sarcomatoid differentiation. Mod Pathol. 2007; 20(2):248-55. DOI: 10.1038/modpathol.3800736. View

Shimizu T, Abe R, Nakamura H, Ohkawara A, Suzuki M, Nishihira J . High expression of macrophage migration inhibitory factor in human melanoma cells and its role in tumor cell growth and angiogenesis. Biochem Biophys Res Commun. 1999; 264(3):751-8. DOI: 10.1006/bbrc.1999.1584. View

Hua-Xiang Xia H, Yang Y, Chu K, Gu Q, Zhang Y, He H . Serum macrophage migration-inhibitory factor as a diagnostic and prognostic biomarker for gastric cancer. Cancer. 2009; 115(23):5441-9. DOI: 10.1002/cncr.24609. View

Suzuki F, Nakamaru Y, Oridate N, Homma A, Nagahashi T, Yamaguchi S . Prognostic significance of cytoplasmic macrophage migration inhibitory factor expression in patients with squamous cell carcinoma of the head and neck treated with concurrent chemoradiotherapy. Oncol Rep. 2004; 13(1):59-64. View

10.

Kao S, Klebe S, Henderson D, Reid G, Chatfield M, Armstrong N . Low calretinin expression and high neutrophil-to-lymphocyte ratio are poor prognostic factors in patients with malignant mesothelioma undergoing extrapleural pneumonectomy. J Thorac Oncol. 2011; 6(11):1923-9. DOI: 10.1097/JTO.0b013e31822a3740. View

11.

Li C, Liu V, Chiu P, Chan D, Ngan H . Over-expressions of AMPK subunits in ovarian carcinomas with significant clinical implications. BMC Cancer. 2012; 12:357. PMC: 3518102. DOI: 10.1186/1471-2407-12-357. View

12.

Adamson I, Prieditis H, Young L . Lung mesothelial cell and fibroblast responses to pleural and alveolar macrophage supernatants and to lavage fluids from crocidolite-exposed rats. Am J Respir Cell Mol Biol. 1997; 16(6):650-6. DOI: 10.1165/ajrcmb.16.6.9191466. View

13.

Lee C, Su M, Huang C, Chen M, Hsu H, Lin C . Macrophage migration inhibitory factor increases cell motility and up-regulates αvβ3 integrin in human chondrosarcoma cells. J Cell Biochem. 2011; 113(5):1590-8. DOI: 10.1002/jcb.24027. View

14.

Gjerdrum C, Tiron C, Hoiby T, Stefansson I, Haugen H, Sandal T . Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival. Proc Natl Acad Sci U S A. 2010; 107(3):1124-9. PMC: 2824310. DOI: 10.1073/pnas.0909333107. View

15.

Binsky I, Haran M, Starlets D, Gore Y, Lantner F, Harpaz N . IL-8 secreted in a macrophage migration-inhibitory factor- and CD74-dependent manner regulates B cell chronic lymphocytic leukemia survival. Proc Natl Acad Sci U S A. 2007; 104(33):13408-13. PMC: 1948950. DOI: 10.1073/pnas.0701553104. View

16.

Meyer-Siegler K, Iczkowski K, Vera P . Further evidence for increased macrophage migration inhibitory factor expression in prostate cancer. BMC Cancer. 2005; 5:73. PMC: 1177932. DOI: 10.1186/1471-2407-5-73. View

17.

Hasani A, Alvarez J, Wyatt J, Bydder S, Millward M, Byrne M . Outcome for patients with malignant pleural mesothelioma referred for Trimodality therapy in Western Australia. J Thorac Oncol. 2009; 4(8):1010-6. DOI: 10.1097/JTO.0b013e3181ae25bf. View

18.

Opitz I, Soltermann A, Abaecherli M, Hinterberger M, Probst-Hensch N, Stahel R . PTEN expression is a strong predictor of survival in mesothelioma patients. Eur J Cardiothorac Surg. 2008; 33(3):502-6. DOI: 10.1016/j.ejcts.2007.09.045. View

19.

Janne P, Wozniak A, Belani C, Keohan M, Ross H, Polikoff J . Pemetrexed alone or in combination with cisplatin in previously treated malignant pleural mesothelioma: outcomes from a phase IIIB expanded access program. J Thorac Oncol. 2007; 1(6):506-12. View

20.

Shi X, Leng L, Wang T, Wang W, Du X, Li J . CD44 is the signaling component of the macrophage migration inhibitory factor-CD74 receptor complex. Immunity. 2006; 25(4):595-606. PMC: 3707630. DOI: 10.1016/j.immuni.2006.08.020. View